All the top Biotech & Pharma news in one daily newsletter.

Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

THE GOOD
Approvals & Labels

GSK's Exdensur (depemokimab) wins EU approval for severe asthma and chronic rhinosinusitis with nasal polyps
Antibody, respiratory disease, monoclonal antibody, severe asthma, IL-5 target, chronic rhinosinusitis - Read more

FDA approves Johnson & Johnson's RYBREVANT FASPRO (amivantamab) monthly dosing for EGFR-mutated non-small cell lung cancer
Antibody, cancer, monoclonal antibody, non-small cell lung cancer, EGFR target, combination therapy - Read more

Harmony Biosciences receives FDA approval for WAKIX (pitolisant) targeting cataplexy in pediatric narcolepsy patients
Small molecule, neurological, histamine receptor antagonist, narcolepsy, pediatric patients, cataplexy - Read more

Shield Therapeutics wins FDA approval for ACCRUFeR (ferric maltol) in children with iron deficiency
Small molecule, metabolic, iron deficiency, pediatric population, ferric maltol - Read more

European Commission approves Novo Nordisk's higher-dose Wegovy (semaglutide) 7.2mg for obesity treatment showing 21% weight loss
Protein therapy, metabolic, GLP-1 receptor agonist, obesity, semaglutide, weight loss - Read more

Cytokinetics' MYQORZO (aficamten) wins European Commission approval for symptomatic obstructive hypertrophic cardiomyopathy treatment
Small molecule, cardiovascular, cardiac myosin inhibitor, hypertrophic cardiomyopathy, aficamten - Read more

PRESENTED BY SCIENCE 2 SALES
We book your meetings. You close the deals.

If you’re selling into biotech or pharma, your highly qualified BD reps should be closing deals and not spending hours cold calling and cold emailing.

Science 2 Sales handles the entire outbound motion - cold calls, emails, and LinkedIn outreach - delivering qualified meetings that actually convert. We speak your prospects' scientific language, so the conversations start at a higher level.

The result? Your pipeline stays full while your reps focus on revenue.

We offer a 30 day money back guarantee on your first month - if we don't deliver, you don't pay.

Book a free strategy call to see how we can help.

✅ More Good News ✅

THE GOOD
Business Development & Partnerships

RoukenBio, AVS Bio partner to improve antibody development through early discovery and preclinical research
Research collaboration, immunology, antibody, drug discovery, R&D - Read more

Novartis, Niowave partner for long-term supply of Actinium-225 radioisotope for targeted cancer therapies
Manufacturing agreement, oncology, radiopharmaceuticals, long-term supply - Read more

Nuclera, leadXpro partner to accelerate membrane protein structure-based drug design using AI-guided screening
Research collaboration, AI/ML, drug discovery, structural biology - Read more

Scribe Therapeutics, Eli Lilly achieve second milestone in CRISPR neurological collaboration, over $1.5B potential milestones
Research collaboration, neurological, gene therapy, milestone payments - Read more

Eli Lilly, CSL license IL-6 inhibitor clazakizumab, $100M upfront plus undisclosed milestones
Licensing deal, cardiovascular, autoimmune, antibody, milestone payments - Read more

BostonGene, Daiichi Sankyo partner on AI-driven ADC development for patient selection, financial terms undisclosed
Research collaboration, oncology, AI/ML, antibody drug conjugate, biomarker development - Read more

Alchemedicine, Asahi Kasei Pharma license HiSAP lead compounds for autoimmune diseases, ¥41.3B ($269M) milestones
Licensing deal, autoimmune, small molecule, milestone payments, global - Read more

Twist Bioscience, Invenra license B-Body bispecific antibody platform for $20M upfront, 6% equity stake
Licensing deal, antibody, drug discovery, equity investment - Read more

THE GOOD
Clinical Trials

Sanofi and Teva report durable 44-week Ph2 results for duvakitug targeting TL1A in inflammatory bowel disease
Antibody, autoimmune, monoclonal antibody, inflammatory bowel disease, TL1A target, ulcerative colitis - Read more

Cyrano Therapeutics' CYR-064 (theophylline) hits Ph2 primary endpoint for persistent post-viral smell loss treatment
Small molecule, neurological, phosphodiesterase inhibitor, anosmia, post-viral smell loss - Read more

Ocular Therapeutix's Axpaxli (tyrosine kinase inhibitor) beats Regeneron's Eylea in Ph3 wet age-related macular degeneration study
Small molecule, ophthalmology, tyrosine kinase inhibitor, wet age-related macular degeneration, hydrogel - Read more

Compass Pathways' COMP360 (psilocybin) shows Ph3 success in treatment-resistant depression with durable effects
Small molecule, neurological, psilocybin, treatment-resistant depression, MADRS endpoint, durability - Read more

Pfizer's Braftovi (encorafenib) triplet shows significant progression-free survival improvement in Ph3 metastatic colorectal cancer trial
Small molecule, cancer, kinase inhibitor, colorectal cancer, BRAF mutation, combination therapy - Read more

Rallybio's RLYB116 C5 inhibitor shows complete terminal complement inhibition in Ph1 study for complement-mediated diseases
Small molecule, autoimmune, C5 inhibitor, complement-mediated diseases, antiphospholipid syndrome - Read more

THE GOOD
Fundraises

Innovacell aims for $92M IPO, cell therapy for urge fecal incontinence treatment
Cell therapy, regenerative medicine, clinical-stage, late-stage biotech - Read more

GelMEDIX raises $13M Seed, developing regenerative therapies to restore vision
Cell therapy, regenerative medicine, ophthalmology, platform technology - Read more

THE GOOD
Investments

Stada invests €85M ($100.8M) to build Saudi Arabia production facility serving Middle East region by 2030
Small molecule, cardiovascular, strategic, major transaction, operational - Read more

THE GOOD
Lawsuits

Bayer strikes $7.25B Roundup settlement to resolve Non-Hodgkin lymphoma litigation over herbicide exposure claims
Herbicide, oncology, financial, major transaction, operational - Read more

PRESENTED BY YOU?
Get the attention of 2500+ Biotech & Pharma Professionals 🤩

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

THE BAD
Clinical Trials

Boehringer Ingelheim terminates Ph1/2 trial of BI 3720931 lentiviral gene therapy for cystic fibrosis
Gene therapy, cystic fibrosis, lentiviral vector, inhaled delivery - Read more

THE UGLY
No Ugly News Today!

You’re all caught up on the latest Pharma & Biotech News!

TLDR Biotech wants to hear from you! 📣

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here